Journal
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Publication Date
5-1-2021
Volume
22
Issue
3-4
First Page
287
Last Page
299
Document Type
Open Access Publication
DOI
10.1080/21678421.2020.1822410
Rights and Permissions
Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Meng L, Wei J, Wolff AA, Malik FI, Bodkin C, Brooks BR, Caress J, Dionne A, Fee D, Goutman SA, Goyal NA, Hardiman O, Hayat G, Heiman-Patterson T, Heitzman D, Henderson RD, Johnston W, Karam C, Kiernan MC, Kolb SJ, Korngut L, Ladha S, Matte G, Mora JS, Needham M, Oskarsson B, Pattee GL, Pioro EP, Pulley M, Quan D, Rezania K, Schellenberg KL, Schultz D, Shoesmith C, Simmons Z, Statland J, Sultan S, Swenson A, Berg LHVD, Vu T, Vucic S, Weiss M, Whyte-Rayson A, Wymer J, Zinman L, Rudnicki SA. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021 May;22(3-4):287-299. doi.org/10.1080/21678421.2020.1822410 © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Recommended Citation
Shefner, Jeremy M.; Miller, Timothy M.; and et al, "A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 22, 3-4. 287 - 299. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11598
